The single-cycle adenovirus platform was developed to enhance the expression of target antigens to amplify immune responses to infectious disease targets. Tetherex is investigating the technology in a phase I open-label study designed to assess the safety, reactogenicity, and immunogenicity of a single-cycle adenovirus vaccine candidate against COVID-19.
The trial is expected to enroll up to 80 healthy volunteers and includes both a single ascending dose group and multiple dose group via either intramuscular or intranasal administration.
Financial details regarding the license agreement were not disclosed.
Copyright © 2021 scienceboard.net